Dose Range Study to Evaluate the Efficacy and Safety of AV5080 in Patients With Influenza

Summary

Assessment of the effect reached with the different doses of AV5080 on the duration and severity of influenza symptoms based on the incidence of their resolution within 96 hours from study treatment initiation compared to Placebo. The absence of influenza symptoms or their reduction to mild severity for at least 24 hours indicates the resolution of influenza.

Timeline

Start

2017-11-13

Primary completion

2019-08-07

Completion

2019-08-30

Drugs

Indications